Compare Carvana Co (CVNA) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Moderna, Inc. — how do they compare? Carvana Co trades at $63.7 (market cap $69.55B), while Moderna, Inc. trades at $220.84 (market cap $78.65B). The key difference: Carvana Co and Moderna, Inc. are close in size by market cap, and Moderna, Inc. is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| CVNA | MRNA | |
|---|---|---|
Market Cap | $69.55B | $78.65B |
Volume | 7,671,750 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $203.46 |
52-Week Low | $56.27 | $22.36 |
Typical Hold Time | 28 Days | — |
Enterprise Value | $72.04B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $64.26, up 2.39% on the day, showing resilience amid a bearish technical signal. The company reported strong revenue growth to $20.32B in 2025 with net income of $1.41B, and has beaten EPS estimates for three consecutive quarters. Positive analyst sentiment is highlighted by a consensus price target of $84.07, though technical indicators suggest near-term caution with key support at $61.
Outlook remains positive due to robust earnings beats and expansion initiatives, but risks include high debt levels and competitive pressures. The stock offers growth potential if operational execution continues, yet investors should monitor cash flow sustainability and market volatility.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
